A consensus definition of cataplexy in mouse models of narcolepsy

Sleep

Volumn 32, Issue 1, 2009, Pages 111-116

  Scammell, Thomas E ^a,e   Willie, Jon T ^b   Guilleminault, Christian ^c   Siegel, Jerome M ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Atonia; Hypocretin; Orexin; Paralysis; Positive affect; REM sleep

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; OREXIN; OXYBATE SODIUM; PHYSOSTIGMINE; PRAZOSIN; PROTRIPTYLINE; VENLAFAXINE; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

CATAPLEXY; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG MECHANISM; ELECTROENCEPHALOGRAM; EMOTION; EXPERIMENTAL ANIMAL; HUMAN; NARCOLEPSY; NONHUMAN; PRIORITY JOURNAL; REM SLEEP; SLEEP WAKING CYCLE; ANIMAL; BRAIN CORTEX; CONSENSUS DEVELOPMENT; DISEASE MODEL; ELECTROENCEPHALOGRAPHY; HYPOTHALAMUS; MOUSE; MUSCLE HYPOTONIA; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CATAPLEXY; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; EMOTIONS; HYPOTHALAMUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MUSCLE HYPOTONIA; NARCOLEPSY; NEUROPEPTIDES; SIGNAL TRANSDUCTION;

EID: 59649094276     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep/32.1.111     Document Type: Conference Paper

References (57)

1. Gélineau J. De la narcolepsie. Gaz Hop (Paris) 1880;53:626-8.
2. Okun ML, Lin L, Pelin Z, Hong S, Mignot E. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002;25:27-35.
3. Krahn LE, Lymp JF, Moore WR, Slocumb N, Silber MH. Characterizing the emotions that trigger cataplexy. J Neuropsychiatry Clin Neurosci 2005;17:45-50.
4. Guilleminault C, Gelb M. Clinical aspects and features of cataplexy. Adv Neurol 1995;67:65-77.
5. Overeem S, Lammers GJ, van Dijk JG. Weak with laughter. Lancet 1999;354:838.
6. Guilleminault C, Pelayo R. Narcolepsy in prepubertal children. Ann Neurol 1998;43:135-42.
7. Serra L, Montagna P, Mignot E, Lugaresi E, Plazzi G. Cataplexy features in childhood narcolepsy. Mov Disord 2008;23:858-65.
8. Guilleminault C, Wilson RA, Dement WC. A study on cataplexy. Arch Neurol 1974;31:255-61.
9. Hishikawa Y, Shimizu T. Physiology of REM sleep, cataplexy, and sleep paralysis. Adv Neurol 1995;67:245-71.
10. Gelb M, Guilleminault C, Kraemer H, et al. Stability of cataplexy over several months - information for the design of therapeutic trials. Sleep 1994;17:265-73.
11. Mignot E, Lammers G, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-62.
12. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7.
13. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74.
14. Crocker A, Espana RA, Papadopoulou M, et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005;65:1184-8.
15. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001;68:686-99.
16. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52:27-78.
17. U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-23.
18. Siegel JM, Tomaszewski KS, Fahringer H, Cave G, Kilduff T, Dement WC. Heart rate and blood pressure changes during sleep-waking cycles and cataplexy in narcoleptic dogs. Am J Physiol 1989;256:H111-9.
19. Siegel JM, Nienhuis R, Fahringer HM, et al. Neuronal activity in narcolepsy: identification of cataplexy-related cells in the medial medulla. Science 1991;252:1315-8.
20. Boehmer LN, Wu MF, John J, Siegel JM. Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity. Exp Neurol 2004;188:292-9.
21. Nishino S, Riehl J, Hong J, Kwan M, Reid M, Mignot E. Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. Neurosci Res 2000;38:437-46.
22. Nishino S, Mignot E, Fruhstorfer B, Dement WC, Hayaishi O. Prostaglandin E2 and its methyl ester reduce cataplexy in canine narcolepsy. Proc Natl Acad Sci U S A 1989;86:2483-7.
23. Fujiki N, Morris L, Mignot E, Nishino S. Analysis of onset location, laterality and propagation of cataplexy in canine narcolepsy. Psychiatry Clin Neurosci 2002;56:275-6.
24. Nishino S, Tafti M, Reid MS, et al. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy. J Neurosci 1995;15:4806-14.
25. Siegel JM, Nienhuis R, Fahringer HM, et al. Activity of medial mesopontine units during cataplexy and sleep- waking states in the narcoleptic dog. J Neurosci 1992;12:1640-6.
26. Siegel JM. Behavioral functions of the reticular formation. Brain Res 1979;180:69-105.
27. Siegel JM, Tomaszewski KS. Behavioral organization of reticular formation: studies in the unrestrained cat. I. Cells related to axial, limb, eye, and other movements. J Neurophysiol 1983;50:696-716.
28. Siegel JM, Tomaszewski KS, Wheeler RL. Behavioral organization of reticular formation: studies in the unrestrained cat. II. Cells related to facial movements. J Neurophysiol 1983;50:717-23.
29. Wu MF, Gulyani SA, Yau E, Mignot E, Phan B, Siegel JM. Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience 1999;91:1389-99.
30. John J, Wu MF, Boehmer LN, Siegel JM. Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. Neuron 2004;42:619-34.
31. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18:9996-10015.
32. Kiyashchenko LI, Mileykovskiy BY, Lai YY, Siegel JM. Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. J Neurophysiol 2001;85:2008-16.
33. Lai YY, Clements JR, Wu XY, et al. Brainstem projections to the ventromedial medulla in cat: retrograde transport horseradish peroxidase and immunohistochemical studies. J Comp Neurol 1999;408:419-36.
34. Mileykovskiy BY, Kiyashchenko LI, Kodama T, Lai YY, Siegel JM. Activation of pontine and medullary motor inhibitory regions reduces discharge in neurons located in the locus coeruleus and the anatomical equivalent of the midbrain locomotor region. J Neurosci 2000;20:8551-8.
35. Gulyani S, Wu MF, Nienhuis R, John J, Siegel JM. Cataplexy-related neurons in the amygdala of the narcoleptic dog. Neuroscience 2002;112:355-65.
36. Aldrich MS, Rogers AE. Exacerbation of human cataplexy by prazosin. Sleep 1989;12:254-6.
37. Reid MS, Tafti M, Geary JN, et al. Cholinergic mechanisms in canine narcolepsy - I. Modulation of cataplexy via local drug administration into the pontine reticular formation. Neuroscience 1994;59:511-22.
38. Lai YY, Siegel JM, Wilson WJ. Effect of blood pressure on medial medulla-induced muscle atonia. Am J Physiol 1987;252:H1249-57.
39. Siegel J, Wilson W, Tomaszewski K. Effect of blood pressure changes on atonia produced by stimulation of the medial medulla. Sleep Res 1984;13:39.
40. Siegel JM, Fahringer H, Tomaszewski KS, Kaitin K, Kilduff T, Dement WC. Heart rate and blood pressure changes associated with cataplexy in canine narcolepsy. Sleep 1986;9:216-21.
41. Lai YY, Siegel JM. Cardiovascular and muscle tone changes produced by microinjection of cholinergic and glutamatergic agonists in dorsolateral pons and medial medulla. Brain Res 1990;514:27-36.
42. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999;98:437-51.
43. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001;30:345-54.
44. Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 2003;38:715-30.
45. Mochizuki T, Crocker A, McCormack S, Yanagisawa M, Sakurai T, Scammell TE. Behavioral state instability in orexin knock-out mice. J Neurosci 2004;24:6291-300.
46. Willie J, Yanagisawa M. Lessons from sleepy mice: narcolepsy-cataplexy and the orexin neuropeptide system. In: Bassetti C, Billiard M, Mignot E, eds. Narcolepsy and hypersomnia. New York: Informa Healthcare, 2007:257-78.
47. España RA, McCormack SL, Mochizuki T, Scammell TE. Running promotes wakefulness and increases cataplexy in orexin knockout mice. Sleep 2007;30:1417-25.
48. Willie J, Chemelli R, Xiong Y, Yanagisawa M. A behavioral paradigm that elicits narcoleptic attacks in orexin knockout mice. Sleep 2000;23:A91-2.
49. Clark E, Baumann C, Cano G, Scammell T, Mochizuki T. Anticipation of food increases cataplexy in orexin knockout mice. In: Annual Meeting of the Society for Neuroscience; 2007; San Diego, 2007. 632.19.
50. Hara J, Yanagisawa M, Sakurai T. Difference in obesity phenotype between orexin-knockout mice and orexin neuron-deficient mice with same genetic background and environmental conditions. Neurosci Lett 2005;380:239-42.
51. Fujiki N, Cheng T, Yoshino F, Nishino S. Specificity of direct transitions from wake to REM sleep in orexin/ataxin-3 narcoleptic mice. Sleep 2006;29:A225.
52. Fujiki N, Cheng T, Yoshino F, Nishino S. Pharmacological evaluation of direct transition from wake to REM sleep (DREM) in orexin/ataxin-3 narcoleptic mice. Sleep 2007;30:A219.
53. International classification of sleep disorders. 2nd ed. Chicago, Illinois: American Academy of Sleep Medicine, 2005.
54. Beuckmann CT, Sinton CM, Williams SC, et al. Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat. J Neurosci 2004;24:4469-77.
55. Zhang S, Lin L, Kaur S, et al. The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats. Neuroscience 2007;148:34-43.
56. Gerashchenko D, Kohls MD, Greco M, et al. Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat. J Neurosci 2001;21:7273-83.
57. McGregor R, Wu F, Boehmer L, Abordo K, Siegel J. Reduced motivated behavior in hypocretin knockout mice. In: Annual Meeting of the Society for Neuroscience; 2007; San Diego, 2007. 97.7.